Download PDF
Endoskopie heute 2008; 21(4): 231-236
DOI: 10.1055/s-0028-1098756
Originalarbeit

© Georg Thieme Verlag Stuttgart ˙ New York

Muzinöse Neoplasien des Pankreas: Übersicht und eigene Erfahrungen

Pancreatic Mucinous Neoplasia: Review and Own ResultsG. Schröder1 , M. Sarbia2 , G. Niedobitek1
  • 1Institute für Pathologie, Sana Klinikum Lichtenberg, Berlin und Unfallkrankenhaus Berlin
  • 2aktuelle Anschrift: Gemeinschaftspraxis Pathologie, Lachnerstr. 2, 80639 München
Further Information

Publication History

Publication Date:
29 December 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zwischen 2000 und 2007 wurden im Sana Klinikum Lichtenberg und im Unfallkrankenhaus Berlin 14 intraduktale papilläre muzinöse Neoplasien (IPMN) und 2 muzinös-zystische Neoplasien (MCN) des Pankreas operiert. Die IPMN-Patienten, 6 Frauen und 8 Männer, waren zwischen 47 und 84 Jahren alt. Fünf IPMN waren im Pankreaskopf, 6 im Korpus bzw. Korpus und Schwanz, 3 im Schwanz lokalisiert. Fünf IPMN waren Borderline-Läsionen, 3 Carcinomata in situ und 6 IPMN-assoziierte Karzinome. Unter den nicht invasiven IPMN fanden sich 5 intestinale, 1 gastraler, 1 pankreatobiliärer und 1 onkozytärer Typ. Beide MCN-Patienten waren weiblich und 69 Jahre bzw. 76 Jahre alt. Es fanden sich ein muzinöses Zystadenom im Pankreaskopf sowie eine muzinös-zystische Borderline-Läsion im Pankreasschwanz. IPMN zeigen eine ausgeglichene Geschlechterverteilung und sitzen meist im Pankreaskopf. MCN kommen nahezu ausschließlich bei Frauen vor, sitzen häufiger im Pankreasschwanz, zeigen ein ovarielles Stroma und kommunizieren anders als IPMN nicht mit dem Pankreasgangsystem. MCN gelten nach R0-Resektion als geheilt. IPMN werden als genetisch determinierte Systemerkrankung des Pankreas mit hoher Rezidivneigung und häufigerer Komalignität angesehen. Die Einteilung der IPMN nach Epitheltyp oder Gangverteilungsmuster (Hauptgangtyp, Tochtergangtyp) hat derzeit keine prognostische Relevanz. 

Abstract

Between 2000 and 2007, 14 intraductal papillary mucinous neoplasms (IPMN) and 2 mucinous cystic neoplasms (MCN) of the pancreas were surgically removed. IPMN patients were 47 to 84 years old, 6 were female and 8 male. Five IPMN were located in the head, 6 in body or body / tail, and 3 in the tail. Five IPMN were borderline lesions, 3 in situ carcinomas, and 6 IPMN-associated carcinomas. Five non-invasive IPMN showed an intestinal type epithelium, 1 a gastral type, 1 a pancreatobiliary type and 1 an oncocytic type. Both MCN patients were females and 69 and 76 years old. A mucinous cystadenoma was located in the pancreatic head, a mucinous-cystic borderline lesion was found in the tail. IPMN show an equal gender distribution and are located predominantly in the pancreatic head while MCN occur almost exclusively in females, are predominantly localised in the tail, are associated with an ovarian stroma and, unlike IPMN, do not communicate with the duct system. Complete resection is curative in MCN. IPMN are genetically determined systemic lesions of the pancreas with high rates of recurrence and malignancy. Classification of IPMN according to epithelial type or location in the pancreatic duct (main duct type, branch duct type) are currently not believed to be prognostically relevant. 

Schlüsselwörter

muzinöse Tumoren - muzinös-zystische Neoplasie - intraduktale papilläre muzinöse Neoplasie - Pankreas - Klassifikation

Key words

mucinous tumours - mucinous-cystic neoplasia - intraductal papillary mucinous neoplasia - pancreas - classification

Literatur

  • 1 Hamilton S R, Aaltonen L A. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon 2000
    Google Scholar
  • 2 Wilentz R E, Albores-Saavedra J, Hruban R H. Mucinous cystic neoplasms of the pancreas.  Semin Diagn Pathol. 2000;  17 31-42
    PubMedGoogle Scholar
  • 3 Adsay N V, Klimstra D S, Compton C C. Cystic lesions of the pancreas. Introduction.  Semin Diagn Pathol. 2000;  17 1-6
    PubMedGoogle Scholar
  • 4 Reddy P R et al. Pancreatic mucinous cystic neoplasms defined by ovarian stroma: Demographics, clinical features and prevalence of cancer.  Clin Gastroenterol and Hepatol. 2004;  2 1026-1031
    CrossrefPubMedGoogle Scholar
  • 5 Tanaka M. Intraductal papillary mucinous neoplasm of the pancreas: diagnosis and treatment.  Pancreas. 2004;  28 282-288
    CrossrefPubMedGoogle Scholar
  • 6 Furukawa T, Klöppel G, Volkan Adsay N et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.  Virchows Arch. 2005;  447 794-799
    CrossrefPubMedGoogle Scholar
  • 7 Adsay N V, Conlon K C, Zee S Y et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients.  Cancer. 2002;  94 62-77
    CrossrefPubMedGoogle Scholar
  • 8 Ban S, Naitoh Y, Mino-Kenudson M et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.  Am J Surg Pathol. 2006;  30 1561-1569
    CrossrefPubMedGoogle Scholar
  • 9 Lüttges J, Zamboni G, Longnecker D et al. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.  Am J Surg Pathol. 2001;  25 942-948
    CrossrefPubMedGoogle Scholar
  • 10 Adsay N V, Merati K, Nassar H et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC 2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas.  Am J Surg Pathol. 2003;  27 571-578
    CrossrefPubMedGoogle Scholar
  • 11 Adsay N V, Merati K, Andea A et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC 1 and MUC 2 supports the existence of two separate pathways of carcinogenesis.  Mod Pathol. 2002;  15 1087-1095
    CrossrefPubMedGoogle Scholar
  • 12 Levi E, Klimstra D S, Andea A et al. MUC 1 and MUC 2 in pancreatic neoplasia.  J Clin Pathol. 2004;  57 456-462 ,  Review. Erratum in: J Clin Pathol 2004; 57: 784
    CrossrefPubMedGoogle Scholar
  • 13 Lüttges J, Feyerabend B, Buchelt T et al. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas.  Am J Surg Pathol. 2002;  26 466-471
    CrossrefPubMedGoogle Scholar
  • 14 Nakamura A, Horinouchi M, Goto M et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.  J Pathol. 2002;  197 201-210
    PubMedGoogle Scholar
  • 15 Goh B K, Tan Y M, Chung Y F et al. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients.  World J Surg. 2006;  30 2236-2245
    CrossrefPubMedGoogle Scholar
  • 16 Tanaka M, Chari S, Adsay V International Association of Pancreatology et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.  Pancreatology. 2006;  6 17-32
    CrossrefPubMedGoogle Scholar
  • 17 Imaoka H et al. Pseudomyxoma peritonei caused by acute pancreatitis in intraductal papillary mucinous carcinoma of the pancreas.  Pancreas. 2006;  32 223-224
    CrossrefPubMedGoogle Scholar
  • 18 Campbell F et al. Cystic neoplasms of the exocrine pancreas.  Histopathology. 2008;  52 539-551
    CrossrefPubMedGoogle Scholar
  • 19 Compagno J, Oertel J E. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases.  Am J Clin Pathol. 1978;  69 573-580
    PubMedGoogle Scholar
  • 20 Naqvi A et al. Borderline mucinous cystic tumor in jejunal pancreatic heterotopia.  Ann Diag Pathol. 2004;  8 151-155
    PubMedGoogle Scholar
  • 21 Lüttges J, Galehdari H, Bröcker V et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.  Am J Pathol. 2001;  158 1561-1563.
    PubMedGoogle Scholar
  • 22 Suzuki Y, Atomi Y, Sugiyama M et al. Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor.  Pancreas. 2004;  28 241-246
    CrossrefPubMedGoogle Scholar
  • 23 Sohn T A, Yeo C J, Cameron J L et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.  Ann Surg. 2004;  239 discussion 797–799 788-797
    CrossrefPubMedGoogle Scholar
  • 24 D'Angelica M, Brennan M F, Suriawinata A A et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.  Ann Surg. 2004;  239 400-408
    PubMedGoogle Scholar
  • 25 Chari S T, Yadav D, Smyrk T C et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.  Gastroenterology. 2002;  123 1500-1507
    CrossrefPubMedGoogle Scholar
  • 26 Yamaguchi K, Ohuchida J, Ohtsuka T et al. Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas.  Pancreatology. 2002;  2 484-490
    CrossrefPubMedGoogle Scholar
  • 27 Sugiyama M, Atomi Y. Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas.  Am J Gastroenterol. 1999;  94 470-473
    CrossrefPubMedGoogle Scholar
  • 28 Ueda M, Miura Y, Kunihiro O et al. MUC 1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).  Hepatogastroenterology. 2005;  52 398-403
    PubMedGoogle Scholar
  • 29 Yonezawa S, Nakamura A, Horinouchi M et al. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms.  J Hepatobiliary Pancreat Surg. 2002;  9 328-341
    CrossrefPubMedGoogle Scholar
  • 30 Lee S Y, Lee K T, Lee J K et al. Long-term follow up results of intraductal papillary mucinous tumors of pancreas.  J Gastroenterol Hepatol. 2005;  20 1379-1384
    CrossrefPubMedGoogle Scholar
  • 31 Sohn T A, Yeo C J, Cameron J L et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.  Ann Surg. 2004;  239 788-797
    CrossrefPubMedGoogle Scholar
  • 32 Adsay N V, Merati K, Basturk O et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas.  Am J Surg Pathol. 2004;  28 839-848
    CrossrefPubMedGoogle Scholar
  • 33 Al-Refaie W B, Choi E A, Tseng J F et al. Intraductal papillary mucinous neoplasms of the pancreas.  Med Princ Pract. 2006;  15 245-252
    CrossrefPubMedGoogle Scholar
  • 34 Sugiyama M, Izumisato Y, Abe N et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.  Br J Surg. 2003;  90 1244-1249
    CrossrefPubMedGoogle Scholar
  • 35 Hruban R H, Takaori K, Klimstra D S et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.  Am J Surg Pathol. 2004;  28 977-987
    CrossrefPubMedGoogle Scholar
  • 36 Matsumoto T, Aramaki M, Yada K et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas.  J Clin Gastroenterol. 2003;  36 261-265
    CrossrefPubMedGoogle Scholar
  • 37 Eguchi H, Ishikawa O, Ohigashi H et al. Role of intraoperative cytology combined with histology in detecting continuous and skip type intraductal cancer existence for intraductal papillary mucinous carcinoma of the pancreas.  Cancer. 2006;  107 2567-2575
    CrossrefPubMedGoogle Scholar

Dr. med. G. Schröder

Institut für Pathologie · Sana Klinikum Lichtenberg

Fanningerstr. 32

10365 Berlin

Phone: 0 30 / 55 18 28 99

Fax: 0 30 / 55 18 28 19

Email: g.schroeder@sana-kl.de

      >